Sales & Marketing News | pharmaphorum

News

US accuses Regeneron of fraud in Eylea price reporting

The US government has filed a lawsuit against Regeneron, claiming that the company falsely inflated the average sales price for ophthalmology blockbuster Eylea to manipula

News

Roche gets EU okay for first HER2-low test kit

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for trea

News

UK calls time-out on post-Brexit rules opposed by industry

It has been more than four years since the UK left the EU, but the government is still being forced to delay the introduction of border control rules that could have conse

News

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors a

News

Carvykti, Abecma move earlier in multiple myeloma treatment

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one pri

News

J&J builds in medtech with $13.1bn Shockwave buy

Johnson & Johnson has reached a deal to acquire Shockwave Medical for around $13.1 billion, expanding its position in medical devices used to treat heart disease.

US accuses Regeneron of fraud in Eylea price reporting

Roche gets EU okay for first HER2-low test kit

UK calls time-out on post-Brexit rules opposed by industry

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

Carvykti, Abecma move earlier in multiple myeloma treatment

J&J builds in medtech with $13.1bn Shockwave buy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks